Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12549092 | 0.85 | HRH4 (0.42) | HRH4CYP1A2CYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL9202114 | 0.78 | HRH4 (0.59) | HRH4HTR3A | |
| SCHEMBL11988216 | 0.72 | ADRB1 (0.49) | HRH4SMN1; SMN2HTR3AKDM4E | |
| SCHEMBL17300732 | 0.71 | HRH4 (0.42) | HRH4CYP1A2CYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL17859911 | 0.71 | KMT2A (0.47) | HRH4CYP1A2CYP2D6CYP2C19KMT2A | |
| SCHEMBL30465897 | 0.70 | HSD17B10 (0.56) | CYP1A2CYP2D6CYP2C19SMN1; SMN2KMT2A | |
| SCHEMBL27082996 | 0.70 | HRH4 (0.59) | HRH4HTR3AKMT2A | |
| SCHEMBL2800977 | 0.70 | HTR3A (0.50) | HRH4SMN1; SMN2HTR3AKMT2AKDM4E | |
| SCHEMBL12903094 | 0.69 | KMT2A (0.55) | HRH4HTR3AKMT2A | |
| SCHEMBL22924659 | 0.69 | KMT2A (0.55) | HRH4HTR3AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3634961-B1 | (4-(([1,2,4]TRIAZOLO[4,3-A]PYRIDINE-6-YL)OXY)-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)UREIDO DERIVATIVES AS ANTI-INFLAMMATORY P38 MAPK INHIBITORS FOR TREATING DISEASES OF THE RESPIRATORY TRACT | CHIESI FARM SPA (IT) | 2021-05-26 | — | — | EP | disclosed |
| EP-3634961-B1 | (4-(([1,2,4]TRIAZOLO[4,3-A]PYRIDINE-6-YL)OXY)-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)UREIDO DERIVATIVES AS ANTI-INFLAMMATORY P38 MAPK INHIBITORS FOR TREATING DISEASES OF THE RESPIRATORY TRACT | CHIESI FARM SPA (IT) | 2021-05-26 | — | — | EP | disclosed |
| EP-3634961-A1 | (4-(([1,2,4]TRIAZOLO[4,3-A]PYRIDINE-6-YL)OXY)-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL) UREIDO DERIVATIVES AS ANTI-INFLAMMATORY P38 MAPK INHIBITORS FOR TREATING DISEASES OF THE RESPIRATORY TRACT | Chiesi Farmaceutici S.p.A. (IT) | 2020-04-15 | — | — | EP | disclosed |
| US-10364245-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-07-30 | — | — | US | disclosed |
| US-10364245-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-07-30 | — | — | US | disclosed |
| US-20180354945-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-12-13 | — | — | US | disclosed |
| WO-2018224423-A1 | (4-(([1,2,4]TRIAZOLO[4,3-A]PYRIDINE-6-YL)OXY)-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL) UREIDO DERIVATIVES AS ANTI-INFLAMMATORY P38 MAPK INHIBITORS FOR TREATING DISEASES OF THE RESPIRATORY TRACT | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180354945-A1 | KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K6 | HRH4 1513/4885CYP1A2 815/4885CYP2D6 1640/4885 |
| US-10364245-B2 | Kinase inhibitors | MAPK1, MAP3K1, MAP3K6 | HRH4 1513/4885CYP1A2 815/4885CYP2D6 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.